Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15914284 | 0.78 | TAAR1 (0.36) | CA2TAAR1LPLLIPGCA12 | |
| SCHEMBL8896663 | 0.76 | IDO1 (0.35) | CA2LPLLIPGALDH1A1SMN1; SMN2 | |
| SCHEMBL81550 | 0.73 | CA2 (0.59) | CA2TAAR1LPLLIPGCA12 | |
| SCHEMBL6089163 | 0.70 | L3MBTL1 (0.50) | CA2TAAR1LPLLIPGALDH1A1 | |
| Hydrochloric Acid SCHEMBL5710261 | 0.68 | L3MBTL1 (0.49) | CA2TAAR1LPLLIPGALDH1A1 | |
| SCHEMBL31728098 | 0.68 | CA2 (0.42) | CA2TAAR1LPLLIPGALDH1A1 | |
| SCHEMBL12911312 | 0.68 | CA2 (0.42) | CA2TAAR1LPLLIPGALDH1A1 | |
| SCHEMBL20128352 | 0.68 | CA2 (0.42) | CA2TAAR1LPLLIPGALDH1A1 | |
| Alcohol SCHEMBL27952977 | 0.67 | LPL (0.57) | CA2TAAR1LPLLIPGALDH1A1 | |
| SCHEMBL12350257 | 0.67 | ALDH1A1 (0.52) | CA2LPLLIPGCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993773-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2015-03-31 | — | — | US | disclosed |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2014-03-27 | — | — | US | disclosed |
| US-8445685-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8173816-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2012-05-08 | — | — | US | disclosed |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2012-03-29 | — | — | US | disclosed |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2011-01-27 | — | — | US | disclosed |
| US-7863300-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-7671207-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2010-03-02 | — | — | US | disclosed |
| US-7465801-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-01-03 | — | — | US | disclosed |
| EP-1521753-B1 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LTD (IN) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167061-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED | 2006-07-27 | — | — | US | disclosed |
| EP-1521753-A2 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LTD. (IN) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007490-A2 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LIMITED (IN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | CA2 4683/4885TAAR1 3889/4885LPL 127/4885 |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | CA2 4641/4885TAAR1 4118/4885LPL 110/4885 |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | CA2 4641/4885TAAR1 4118/4885LPL 110/4885 |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | CA2 4641/4885TAAR1 4118/4885LPL 110/4885 |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | CA2 4641/4885TAAR1 4118/4885LPL 110/4885 |
| US-20060167061-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | CA2 4641/4885TAAR1 4118/4885LPL 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.